Migraine drug up for FDA review
Biotech company says approval would result in increased workforce
By Luther Turmelle luther.turmelle@hearstmediact.com
BUSINESS
NEW HAVEN — A biopharmaceutical company based in the city said in a regulatory filing last week that the federal Food and Drug Administration has accepted its new drug application for treatment and prevention of migraine headaches.
The Oct. 3 filing...
Read latest New Haven Register (New Haven, CT) online.
Online newspapers
at PressDisplay.